| Continuous characteristics | Correlation (RS) | RSP |
| Number of patients included | 0.47 | .03 |
| Median age of patients included | 0.1 | .65 |
| Number of events | 0.47 | .02 |
| Median follow-up | −0.41 | .08 |
| Journal impact factor | 0.56 | .006 |
| Hazard ratio | −0.60 | .009 |
| Categorical characteristics | FI (IQR) | P |
| Publication year | .81 | |
| 2010 ≤ publication year < 2015 | 23.5 (10.5-32.0) | |
| 2015 ≤ publication year < 2018 | 11.0 (6-38.5) | |
| 2018 ≤ publication year ≤ 2021 | 29.0 (20.3-34.8) | |
| Treatment line | .14 | |
| First line | 17.5 (6-34) | |
| Relapsed/refractory | 31 (25-51.5) |
| Continuous characteristics | Correlation (RS) | RSP |
| Number of patients included | 0.47 | .03 |
| Median age of patients included | 0.1 | .65 |
| Number of events | 0.47 | .02 |
| Median follow-up | −0.41 | .08 |
| Journal impact factor | 0.56 | .006 |
| Hazard ratio | −0.60 | .009 |
| Categorical characteristics | FI (IQR) | P |
| Publication year | .81 | |
| 2010 ≤ publication year < 2015 | 23.5 (10.5-32.0) | |
| 2015 ≤ publication year < 2018 | 11.0 (6-38.5) | |
| 2018 ≤ publication year ≤ 2021 | 29.0 (20.3-34.8) | |
| Treatment line | .14 | |
| First line | 17.5 (6-34) | |
| Relapsed/refractory | 31 (25-51.5) |
IQR, interquartile range.